Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday).
Francis Crick Institute researchers, funded by Cancer Research UK, have shown that skin, breast and bowel cancer cells often produce large amounts of prostaglandin E2 (PGE2). This molecule dampens down the immune system’s normal response to attack faulty cells, which helps cancer to hide. It is a trick that allows the tumour to thrive and may explain why some immunotherapy treatments have not been as effective as hoped.
Aspirin is part of a group of molecules called COX inhibitors, which stop the production of PGE2 and help reawaken the immune system. Combining immunotherapy with aspirin or other COX inhibitors substantially slowed bowel and melanoma skin cancer growth in mice, compared to immunotherapy alone*.
Study author Professor Caetano Reis e Sousa, senior group leader at the Francis Crick Institute, said: “We’ve added to the growing evidence that some cancers produce PGE2 as a way of escaping the immune system. If you can take away cancer cells’ ability to make PGE2 you effectively lift this protective barrier and unleash the full power of the immune system.
“Giving patients COX inhibitors like aspirin at the same time as immunotherapy could potentially make a huge difference to the benefit they get from treatment. It’s still early work but this could help make cancer immunotherapy even more effective, delivering life-changing results for patients.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Improved Cancer Immunotherapy Predicted Through Math Modelson February 3, 2020 at 12:32 pm
can predict how tumors may respond to immunotherapy, and how adding other anti-cancer drugs could lead to improved treatment. ‘The identification of tumor perfusion as key to the efficacy of ...
- Cold plasma patch could make immunotherapy more effective for treating melanomaon February 3, 2020 at 12:04 pm
"Immunotherapy is one of the most groundbreaking advances in cancer treatment," said study senior author Zhen Gu, professor of bioengineering at the UCLA Samueli School of Engineering and member of ...
- Math models add up to improved cancer immunotherapyon February 3, 2020 at 12:01 pm
Immune checkpoint inhibitors such as Keytruda (pembrolizumab) and Opdivo (nivolumab) have greatly improved treatment for more than a dozen malignancies, including non-small cell lung cancer, kidney ...
- Cancer Immunotherapy Market 2020 Clinical Survey Report – Roche, Bayer, Eli Lilly, Merck, Novartison February 1, 2020 at 12:39 am
The Cancer Immunotherapy Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants ...
- Enhancing cancer immunotherapy with nanomedicineon January 31, 2020 at 5:49 am
Therapeutic targeting of the immune system in cancer is now a clinical reality and marked successes have been achieved, most notably through the use of checkpoint blockade antibodies and chimeric ...
- Cancer Immunotherapy Market is Expected to Garner Higher Revenues between 2020-2025on January 30, 2020 at 9:55 am
New York, January 30, 2020: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled ...
- Immunotherapy called ‘the future of cancer care,’ but not without risks, costs: Health Matterson January 30, 2020 at 8:27 am
Q: What is immunotherapy, and what kinds of cancer can it treat? A: Immunotherapy is a cancer treatment that activates a patient’s immune system to identify and destroy diseases such as cancer.
- Cancer Immunotherapy Market Size to Hit US$ 115.4 Bn by 2026on January 30, 2020 at 7:38 am
The global cancer immunotherapy market is expected to grow at a noteworthy CAGR of around 10.6% during the forecast period 2019 to 2026 LOS ANGELES, Jan. 30, 2020 /PRNewswire/ -- The Cancer ...
- Global cancer immunotherapy market is expected to grow with a CAGR of 15.12% over the forecast period from 2019-2025on January 28, 2020 at 9:20 am
The report on the global cancer immunotherapy market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global cancer immunotherapy market to grow ...
- HPV-Cancer Targeting Immunotherapy Enters Phase 1 Clinical Trial After Showing Success In Animalson January 24, 2020 at 6:40 am
The paper highlights the candidate’s ability to target and shrink HPV motivated tumors in both animal studies and human blood samples.
via Bing News